Lomotil and Injection site mass - a phase IV clinical study of FDA data

Summary:

Injection site mass is reported as a side effect among people who take Lomotil (atropine sulfate; diphenoxylate hydrochloride), especially for people who are female, 50-59 old, also take Vitamin B12, and have Thyroid diseases.

The phase IV clinical study analyzes which people have Injection site mass when taking Lomotil. It is created by eHealthMe based on reports of 18,891 people who have side effects when taking Lomotil from the FDA, and is updated regularly.

What is Lomotil?

Lomotil has active ingredients of atropine sulfate; diphenoxylate hydrochloride. It is often used in diarrhea. eHealthMe is studying from 19,184 Lomotil users. Check the latest studies of Lomotil.

What is Injection site mass?

Injection site mass is found to be associated with 832 drugs and 787 conditions by eHealthMe. Check the latest studies of Injection site mass.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

18,891 people reported to have side effects when taking Lomotil.
Among them, 62 people (0.33%) have Injection site mass.

Could Lomotil cause Injection site mass?

Among these 62 people:

What is the gender of people who have Injection site mass when taking Lomotil? *

female: 85.48 %
male: 14.52 %

What is the age of people who have Injection site mass when taking Lomotil? *

What are other drugs people take besides Lomotil? *

What are other side effects people have besides Injection site mass? *

Injection Site Pain: 42 people, 67.74%
Injection Site Erythema (redness at injection site): 34 people, 54.84%
Nasopharyngitis (inflammation of the nasopharynx): 28 people, 45.16%
Malaise (a feeling of general discomfort or uneasiness): 27 people, 43.55%
Dizziness: 27 people, 43.55%
Nausea (feeling of having an urge to vomit): 25 people, 40.32%
Nausea And Vomiting: 25 people, 40.32%
Drowsiness: 24 people, 38.71%
Headache (pain in head): 24 people, 38.71%
Cough: 23 people, 37.10%

What are the existing conditions these people have? *

Thyroid Diseases: 22 people, 35.48%
Neuroendocrine Tumor: 19 people, 30.65%
Diabetes: 14 people, 22.58%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 12 people, 19.35%
Serum Ferritin Decreased: 6 people, 9.68%
Pain: 5 people, 8.06%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 8.06%
High Blood Cholesterol: 4 people, 6.45%
Osteoporosis (bones weak and more likely to break): 4 people, 6.45%
High Blood Pressure: 4 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Lomotil and have Injection site mass?

- Check whether Injection site mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lomotil:

Lomotil (19,184 reports)

Injection site mass treatments and more:

Injection site mass (37,511 reports)

How severe was Injection site mass and when was it recovered:

Injection site mass in Lomotil

Expand to all the drugs that have ingredients of atropine sulfate; diphenoxylate hydrochloride:

Injection site mass and drugs with ingredients of atropine sulfate; diphenoxylate hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lomotil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site mass:

Injection site mass (832 drugs)

Browse all the conditions that are associated with Injection site mass:

Injection site mass (787 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atropine sulfate; diphenoxylate hydrochloride (the active ingredients of Lomotil) and Lomotil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.